Prognostic value of a 6-minute walk test in patients with transthyretin cardiac amyloidosis.

Ioannou, Adam; Fumagalli, Carlo; Razvi, Yousuf; Porcari, Aldostefano; Rauf, Muhammad U; Martinez-Naharro, Ana; Venneri, Lucia; Moody, William; Steeds, Richard P; Petrie, Aviva; Whelan, Carol; Wechalekar, Ashutosh; Lachmann, Helen; Hawkins, Philip N; Solomon, Scott D; Gillmore, Julian D; Fontana, Marianna

Publication

Prognostic value of a 6-minute walk test in patients with transthyretin cardiac amyloidosis.

Abstract

Background: The 6-minute walk test (6MWT) represents a comprehensive functional assessment that is commonly used in patients with heart failure; however, data are lacking in patients with transthyretin cardiac amyloidosis (ATTR-CA). Objectives: This study aimed to assess the prognostic importance of the 6MWT in patients with ATTR-CA. Methods: A retrospective analysis of patients diagnosed with ATTR-CA at the National Amyloidosis Centre who underwent a baseline 6MWT between 2011 and 2023 identified 2,141 patients, of whom 1,118 had follow-up at 1 year. Results: The median baseline 6MWT distance was 347 m (Q1-Q3: 250-428 m) and analysis by quartiles demonstrated an increased death rate with each distance reduction (deaths per 100 person-years: 6.3 vs 9.2 vs 13.6 vs 19.0; log-rank P < 0.001). A 6MWT distance of <350 m was associated with a 2.2-fold higher risk of mortality (HR: 2.15; 95% CI: 1.85-2.50; P < 0.001), with a similar increased risk across National Amyloidosis Centre disease stages (P for interaction = 0.761) and genotypes (P for interaction = 0.172). An absolute (reduction of >35 m) and relative worsening (reduction of >5%) of 6MWT at 1 year was associated with an increased risk of mortality (HR: 1.80; 95% CI: 1.51-2.15; P < 0.001 and HR: 1.89; 95% CI: 1.59-2.24; P < 0.001, respectively), which was similar across the aforementioned subgroups. When combined with established measures of disease progression (N-terminal pro-B-type natriuretic peptide progression and outpatient diuretic intensification), each incremental increase in progression markers was associated with an increased death rate (deaths per 100 person-years: 7.6 vs 13.9 vs 22.4 vs 32.9; log-rank P < 0.001). Conclusions: The baseline 6MWT distance can refine risk stratification beyond traditional prognosticators. A worsening 6MWT distance can stratify disease progression and, when combined with established markers, identifies patients at the highest risk of mortality.

Author

Ioannou, Adam
Fumagalli, Carlo
Razvi, Yousuf
Porcari, Aldostefano
Rauf, Muhammad U
Martinez-Naharro, Ana
Venneri, Lucia
Moody, William
Steeds, Richard P
Petrie, Aviva
Whelan, Carol
Wechalekar, Ashutosh
Lachmann, Helen
Hawkins, Philip N
Solomon, Scott D
Gillmore, Julian D
Fontana, Marianna

Date

2024-05-13

Type

Article

Subject

Cardiology

Collections

UHB Cardiology

Show all metadata

Citation

Ioannou A, Fumagalli C, Razvi Y, Porcari A, Rauf MU, Martinez-Naharro A, Venneri L, Moody W, Steeds RP, Petrie A, Whelan C, Wechalekar A, Lachmann H, Hawkins PN, Solomon SD, Gillmore JD, Fontana M. Prognostic Value of a 6-Minute Walk Test in Patients With Transthyretin Cardiac Amyloidosis. J Am Coll Cardiol. 2024 Jul 2;84(1):43-58. doi: 10.1016/j.jacc.2024.04.011. Epub 2024 May 13.

Journal / Source Title

Journal of the American College of Cardiology

DOI

10.1016/j.jacc.2024.04.011

URI

http://hdl.handle.net/20.500.14200/5068

PMID

38739065

Publisher

Elsevier

Publisher’s URL

https://www.sciencedirect.com/journal/journal-of-the-american-college-of-cardiology